Journal article
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
JH Elliott, JH McMahon, CC Chang, SA Lee, W Hartogensis, N Bumpus, R Savic, J Roney, R Hoh, A Solomon, M Piatak, RJ Gorelick, J Lifson, P Bacchetti, SG Deeks, SR Lewin
Lancet HIV | ELSEVIER INC | Published : 2015
Abstract
Background In vitro, disulfiram activated HIV transcription in a primary T-cell model of HIV latency and in a pilot clinical study increased plasma HIV RNA in individuals with adequate drug exposure. We assessed the effect of disulfiram on HIV transcription in a dose-escalation study. Methods In this prospective dose-escalation study, to optimise disulfiram exposure we included adults with HIV on suppressive antiretroviral therapy, with plasma HIV RNA of less than 50 copies per mL and a CD4 cell count greater than 350 cells per μL. Participants were allocated sequentially to one of three dosing groups (500 mg, 1000 mg, and 2000 mg) and received disulfiram daily for 3 days. Only the staff who..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
We acknowledge the participation and commitment of study participants, which made the study possible, and the contribution of the Alfred Hospital Infectious Diseases Clinical Research Unit, Melbourne, VIC, Australia, particularly Michelle Hagenauer. The study was supported by a research grant from the Foundation for AIDS Research (amfAR; 108465-52-RGRL) and additional support from the Division of AIDS, National Institute of Allergy and Infectious Diseases, US National Institutes of Health (DARE: Delaney AIDS Research Enterprise; U19AI096109). Additional support came from NIAID (K24 AI069994), the UCSF/Gladstone Institute of Virology & Immunology CFAR (P30 AI027763), the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E, and the UCSF Clinical and Translational Research Institute Clinical Research Center (UL1 RR024131). SRL is funded from an Australian National Health and Medical Research Council (NHMRC) Practitioner Fellowship. JHE and CCC are recipients of Australian NHMRC Early Career Fellowships. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organisations imply endorsement by the US Government.